We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Global In Vitro Diagnostics (IVD) Quality Control Market Projected to Reach USD 1.4 Billion by 2026

By LabMedica International staff writers
Posted on 08 Sep 2021
Print article
Illustration
Illustration
The global in vitro diagnostics (IVD) quality control market is projected to grow at a CAGR of 5.3% from USD 1.1 billion in 2021 to USD 1.4 billion by 2026, thanks to the significant role played by IVD testing in clinical decision-making.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a provider of quantified B2B research.

Over the years, IVD quality control products and procedures have become mandatory in accredited clinical or medical laboratories. The applications of IVD quality control products have also widened over the years, with a number of quality controls currently available in the market for clinical chemistry, immunochemistry, hematology, molecular diagnostics, coagulation, and microbiology. To ensure technological competitiveness, companies are continuously launching innovative and advanced quality control products in the market for a variety of applications.

The growth of the IVD quality control market is primarily driven by the rising number of accredited clinical laboratories, increasing geriatric population, growing demand for external quality assessment programs, increasing adoption of POC instruments in the developed regions, and rising adoption of third-party quality controls. The increasing focus on multi-analyte controls is also expected to offer significant growth opportunities for the market in the coming years. The use of quality control products is, however, not mandatory for all clinical laboratories in many countries. The lack of regulations for these products is expected to adversely affect market growth.

Based on product & service, the quality control products segment accounted for the largest share of the IVD quality control market in 2020, mainly due to the increasing number of accredited laboratories and mandates for the use of quality controls from regulatory bodies to ensure the accuracy of diagnostic test results. On the basis of technology, the immunochemistry segment held the largest share of the IVD quality control market in 2020 which can be attributed to the increasing use of multi-analyte controls for performing immunoassay tests in laboratories. The use of immunoassay tests in clinical laboratories has also increased due to the high sensitivity of these tests in comparison to conventional methods.

Based on manufacturer, the third-party controls segment accounted for the largest share of the global IVD quality control market in 2020, led by the increasing use of third-party quality controls across the world to verify the accuracy and reliability of tests. On the basis of end user, the hospitals segment accounted for the largest share of the IVD quality control market in 2020, owing to the large volume of diagnostic tests carried out in hospitals.

Geographically, North America accounted for the largest share of the global IVD quality control market in 2020, followed by Europe. Recommendations for and approvals of quality control products from the FDA and the College of American Pathologists (CAP) and the presence of well-established distribution channels and leading companies in the US are driving the IVD quality control market in North America.


Related Links:
MarketsandMarkets

Gold Supplier
SARS-CoV-2 Antibody Test
SARS-CoV-2 UTAB FS
New
Silver Supplier
Automated Nucleic Acid Extractor
NE48/96
New
Single Channel Pipette
AHN pipet4u pro
New
IFA Automated Processor
ZEUS IF Elite

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.